Vir Biotechnology (VIR) Income from Continuing Operations (2018 - 2026)

Vir Biotechnology has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 125695000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 125695000.0, down 3.91% year-over-year; the trailing twelve-month figure through Mar 2026 was 442717000.0 (up 23.36% YoY), and the FY2025 annual result was 437987000.0, up 16.09% from the prior year.
• Income from Continuing Operations came in at 125695000.0 for Q1 2026 at Vir Biotechnology, down from 42923000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 518621000.0 in Q1 2022 to a low of 213717000.0 in Q3 2024.
• The 5-year median for Income from Continuing Operations is 115973000.0 (2023), against an average of 69701294.12.
• Peak annual rise in Income from Continuing Operations reached 407.04% in 2022, while the deepest fall reached 223.75% in 2022.
• Vir Biotechnology's Income from Continuing Operations stood at 101603000.0 in 2022, then decreased by 14.14% to 115973000.0 in 2023, then advanced by 9.82% to 104589000.0 in 2024, then soared by 58.96% to 42923000.0 in 2025, then tumbled by 192.84% to 125695000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 125695000.0 (Q1 2026), 42923000.0 (Q4 2025), and 163141000.0 (Q3 2025), per Business Quant data.